Rapamycin (Sirolimus) 化学構造
分子量: 914.18

高品質保証

文献中の引用(62)

カスタマーフィードバック(12)

Quality Control & MSDS

製品説明

  • Compare mTOR Inhibitors
    mTOR製品生物活性の比較
  • 研究分野
  • Combination Therapy
    併用療法

製品の説明

生物活性

製品説明 Rapamycin (Sirolimus) は、特定のmTOR阻害剤で、IC50 が ~0.1 nMです。
ターゲット

mTOR

IC50

~0.1 nM [1]

In vitro試験 Rapamycin inhibits endogenous mTOR activity in HEK293 cells with IC50 of ~0.1 nM, more potently than iRap and AP21967 with IC50 of ~5 nM and ~10 nM, respectively. [1] In Saccharomyces cerevisiae, Rapamycin treatment induces a severe G1/S cell cycle arrest and inhibition of translation initiation to levels below 20% of control. [2] Rapamycin significantly inhibits the cell viability of T98G and U87-MG in a dose-dependent manner with IC50 of 2 nM and 1 μM, respectively, while displaying little activity against U373-MG cells with IC50 of >25 μM despite the similar extent of the inhibition of mTOR signaling. Rapamycin (100 nM) induces G1 arrest and autophagy but not apoptosis in Rapamycin-sensitive U87-MG and T98G cells by inhibiting the function of mTOR. [3]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
HT-29 MnXUR5l1d3SxeHnjJGF{e2G7 MkPVNVAhdk1? Ml7VO|IhcA>? MmX0SG1UVw>? M4jJNnBwfGWwdHnheIV{KGOjbYD0c5Rp\WOrbj3pcoR2[2WmIHP5eI91d3irY3n0fS=> NInlXIozPDlyMEi3Ny=>
HT-29 M2LNcWN6fG:2b4jpZ{BCe3OjeR?= NHuzXmEyOCCwTR?= MVS3NkBp M{DoNWROW09? M3zJd3BwfGWwdHnheIV{KGSrZ3n0c5hqdi2rbnT1Z4VlKGO7dH;0c5hq[2m2eR?= M4\mNlI1QTByOEez
HT-29 MlnXR5l1d3SxeHnjJGF{e2G7 NFfMbIoyOCCwTR?= M2P4XVczKGh? NHm5cXdFVVOR M2jzeXBwfGWwdHnheIV{KDVvZnz1c5JwfXKjY3nsMYlv\HWlZXSgZ5l1d3SxeHnjbZR6 NXz2VZVUOjR7MEC4O|M>
PC3 MVHLbY5ie2ViQYPzZZk> NHvlR4syODBibl2= M3;VNVEhcA>? Mk\sSG1UVw>? MnnxVI91\W62bImgbY5pcWKrdIOgcXRQWi2vZXTpZZRm\CCVNjDwbI9{eGixconsZZRqd25id3n0bEBKSzVyIH;mJFwyOCCwTT6= MlzQNlE6Pzh4OEO=
PC3 M4DlfWtqdmG|ZTDBd5NigQ>? NGrSU3QyODBibl2= NGXjclkyKGh? NV;N[po{TE2VTx?= MYjEc4V{KG6xdDDpcohq[mm2IH3UU3IudWWmaXH0[YQhSWu2IIDoc5NxcG:{eXzheIlwdg>? NIjUbWozOTl5OE[4Ny=>
PC3 NYq5d5RJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUCxMlUh|ryP M3fBSlEhcA>? NUi1cGJKTE2VTx?= MnzPTY5lfWOnczDhcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFCFMzDj[YxteyC5aYToJGlEPTBib3[gQFExKG6P MUSyNVk4QDZ6Mx?=
HEK293 MV\GeY5kfGmxbjDBd5NigQ>? NHXrV48yODBibl2= NGDHVnA5KGh? MkDMSG1UVw>? NHPvcmNKdmirYnn0d{BVWEFvaX7keYNm\CCmZXfyZYRifGmxbjDv[kBR\GOmNDD3bZRpKEWFNUCgc4YhPTBibl2= NI\D[HUzOTV|OUOwNS=>
BT-20 MlPsT4lv[XOnIFHzd4F6 MXOyNEDPxE1? M2TXRWROW09? NF25NWdFd2W|IH7veEBqdmirYnn0JI1VV1KFMjDk[ZBmdmSnboSgdGFsXCCVNEezJJBpd3OyaH;yfYxifGmxbh?= MXGyNVM2OzV3MR?=
U937 NIDlWnBCdnSrYnHjeIVzcWGuIFHzd4F6 NGXWNmE2OCEQvF2= MXm0PEBp NWfYToQ3TE2VTx?= M2nBUGlv\HWlZYOgZY51cWKjY4TldolidCCjY4Tpeol1gSCjZ3HpcpN1KHerbHSgeJlx\SCOZXfpc45mdGyjIIDu[ZVud3CqaXzhJHBpcWyjZHXsdIhq[S1zIFrSN|IhcW5iVUmzO{Bk\Wyucx?= MVeyNVE1OjFyNh?=
U937 NF7mdmxCdnSrYnHjeIVzcWGuIFHzd4F6 M3vhOVUxKM7:TR?= MX60PEBp M3;ITGROW09? NV22fFIyTG:nczDuc5QhcW6mdXPlJIFvfGmkYXP0[ZJq[WxiYXP0bZZqfHliYXfhbY5{fCCPSWCgdJJwfGWrbj3k[YZq[2mnboSgUIVocW:wZXzsZUBxdmW3bX;wbIlt[SCMUkOyMVIhcW5iVUmzO{Bk\Wyucx?= M{TRbVIyOTR{MUC2
U937 MmTHRY51cWKjY4TldolidCCDc4PhfS=> M1jvO|UxKM7:TR?= MnfhOFghcA>? Mo\TSG1UVw>? NVTKWHlKTG:nczDuc5QhcW6mdXPlJIFvfGmkYXP0[ZJq[WxiYXP0bZZqfHliYXfhbY5{fCCHc3Po[ZJq[2irYTDjc4xqKEiEMUCxJIlvKFV7M{egZ4VtdHN? NF;aO2QzOTF2MkGwOi=>
MCF-7 M1j0fWF2fG:yaHHnfUBCe3OjeR?= M{nBWlMxKG6P NHHCe4g1KGh? NGX3Z25FVVOR NUKzdIR2UW6mdXPld{BifXSxcHjh[5k> NGf6dVgzODB{OEGzOC=>
U87MG M17JVmtqdmG|ZTDBd5NigQ>? MUKxJO69VQ>? MnjCOkBp NY\JZ4VzTE2VTx?= NHXJd3dRd3SnboTsfUBqdmirYnn0d{BuXE:ULX3l[IlifGWmIGO2JJBpd3OyaH;yfYxifGmxbh?= M{HhU|E6QDR6NEC0
U87MG NFLEO|VMcW6jc3WgRZN{[Xl? NYf4cG5tOSEQvF2= NUXnXZNpPiCq NFL0cmNFVVOR NVvoboFUWG:2ZX70cJkhcW6qaXLpeJMhPEWEUEGoWFcxMSCyaH;zdIhwenmuYYTpc44> NF;ZfVIyQTh2OESwOC=>
U87MG MWjLbY5ie2ViQYPzZZk> M2LhTVEh|ryP M1zzRVYhcA>? Mn3NSG1UVw>? M1ewcWRw\XNibn;0JIlvcGmkaYSgcXRQWi2vZXTpZZRm\CCDa4SgdIhwe3Cqb4L5cIF1cW:w M1njZlE6QDR6NEC0
U87MG NHz6eYlMcW6jc3WgRZN{[Xl? MXSxJO69VQ>? MoTQOkBp M3;JfWROW09? NIDQO2dFd2W|IH7veEBqdmirYnn0JHAuPEWEUEGoWFM4NzR4KTDwbI9{eGixconsZZRqd25? M3Prc|E6QDR6NEC0
COS7 cells expressing EGFP-HDQ74/rheb M4Dr[GF2fG:yaHHnfUBCe3OjeR?= MknHNE4zKM7:TR?= NYnFXlEzOjRiaB?= NUDBT4IyTE2VTx?= NHPncmhKdmS3Y3XzJIF2fG:yaHHnfS=> NYXYe3ZGOTh|OUG5OFk>
COS7 cells expressing EGFP-LC3 NX;ZWJQySXW2b4DoZYd6KEG|c3H5 Mm\TNE4zKM7:TR?= MnXsNlQhcA>? MXzEUXNQ NUTqeGE5UW6mdXPld{BifXSxcHjh[5k> MUWxPFM6OTl2OR?=
H4 MYrGeY5kfGmxbjDBd5NigQ>? MXmwMlIh|ryP MlXMNlQhcA>? M4izfGROW09? M3zXdmlv[3KnYYPld{B1cGVicnH0bY8hd2ZibHnnbJQh[2ijaX6gN{B{fWK3bnn0JFIhfG9ibHnnbJQh[2ijaX6gN{B{fWK3bnn0JFEhcW5iaIXtZY4hUDRiY3XscJM> MoO4NVgxOjR3OES=
HeLa NW\y[GluTnWwY4Tpc44hSXO|YYm= MWmxNFAhdk1? MYOzOkBp NGTtc4xFVVOR NXHxc2c3UW6mdXPld{BHWkJiS{KwPVVRNCCWMkC5PGwtKFd{MUCxSkBufXSjboSteYJqeXWrdHnuR{BqdnSncnHjeIlwdg>? NGjCfGcyPzV4M{O4OS=>
HeLa MYHGeY5kfGmxbjDBd5NigQ>? MUexNFAhdk1? NFnx[Go{PiCq M3u5SmROW09? NGTpSJZKdmS3Y3XzJGZTSiCZMkGwNWYhdXW2YX70MZVjcXG3aYTpcmMhcW62ZYLhZ5Rqd25? MnLRNVc2PjN|OEW=
HeLa MlvESpVv[3Srb36gRZN{[Xl? NXnCRnRZOTByIH7N MWOzOkBp NVGxd5lxTE2VTx?= NWPkWI04UW6mdXPld{BHWkJvRlvCVEBkd22ybHX4JIlvfGW{YXP0bY9v NV\nN5FsOTd3NkOzPFU>
SYF NUHqS|E1TnWwY4Tpc44hSXO|YYm= MYSxNFAhdk1? MmH2NlQhcA>? NWW1SVViTE2VTx?= Mke2TY5lfWOnczDGVmIuTkuEUDDjc41xdGW6IHnueIVz[WO2aX;u NWK3cpBsOTd3NkOzPFU>
SYF NYPPVmxQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHNcGVWOTByIH7N MoDpNlQhcA>? M1TQcmROW09? MXjJcoR2[2W|IHHueIlxem:uaX\ldoF1cX[nIHHjeIl3cXS7IHHnZYlve3RiU2nGJINmdGy| MYWxO|U3OzN6NR?=
HEK293T MYjBcpRqfmm{YXygRZN{[Xl? MlLUNUBvVQ>? NHjhXmE1KGR? M3nUdGROW09? NIfXU5BKdmS3Y3XzJIFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhKXjFiUkWge4l1cCCHQ{WwJI9nKDBwMTDuUS=> NVPhNmJCOTd2OEW1NFE>
HEK293T M4jweWFvfGm4aYLhcEBCe3OjeR?= MnLKNUBvVQ>? NFjXd3M1KGR? NWrDUFJVTE2VTx?= NH3CZWlKdmS3Y3XzJIFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhKXjFiWESge4l1cCCHQ{WwJI9nKDBwMzDuUS=> NH[wOW8yPzR6NUWwNS=>
PBMC MVrGeY5kfGmxbjDBd5NigQ>? MmjTNUBvVQ>? MnvwNVQh\A>? NFXyO5RFVVOR MXTS[YR2[2W|IFPDVlUh\GWwc3n0fS=> NXnFNZFyOTd2OEW1NFE>
PBMC M1vqXWZ2dmO2aX;uJGF{e2G7 MoHiNUBvVQ>? NVvKcFViOTRiZB?= MXvEUXNQ MVvEc4V{KG6xdDDh[oZm[3RiQ2jDVlQh\GWwc3n0fS=> MXOxO|Q5PTVyMR?=
HEK293 cells NFS2U3RMcW6jc3WgRZN{[Xl? M1TDfVUxKG6P NYPWc5NyPDVibXnu MVrEUXNQ M1PFZ2lvcGmkaYTzJI1VV1Jia3nuZZNmKGGldHn2bZR6KHerdHigTWM2OCCxZjCwMlEhdk1? MWOxO|M2ODl3Mx?=
Drosophila melanogaster S2 cells transfected with N-luc and C-luc NYHSNGJGTnWwY4Tpc44hSXO|YYm= MnjCNVAxKG6P NVrsdVdmPCCq MVXEUXNQ M{PZW2lv\HWlZYOgcJVkcW[ncnHz[UBxem:2ZXnuJJRz[W6|LYPwcIlkcW6pIHnuJGRzd3OxcHjpcIEhdWWuYX7v[4F{fGW{IGOyJINmdGy|IITyZY5{\mWldHXkJJdqfGhiTj3seYMh[W6mIFOtcJVk NHXrcHgyPzF{OEK2Ni=>
Human mixed lymphocyte M3i0T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHBfmE2KG6P NULWUVJmTE2VTx?= MVTJR|UxRTFwNjDuUU4> NIXuSnoyPjF6NUi2OS=>
Lewis rat lymph node cells M3rwfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVKwXVlUPSEQvF2= NUf3UZRwTE2VTx?= NEXVfo5KSzVyPUKuOkDPxE1? Mlj3NVYyQDV6NkW=
cells from the thymus of normal BALB/c mice M3rzWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XwV|ExKG6P MoTFO|IhcA>? MWrEUXNQ MkTyTY5pcWKrdIOgcJlueGixcILvcIln\XKjdHnvckApVEGIKTD3bZRpKEmFNUCgc4YhOyCwTR?= NYmyXJg4OTByMkG5OFg>
MRK-nu-1 Mn2wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{[3O2lEPTB;MD64OFUheE1? NE[zOXdUSU6JRWK=
OCUB-M MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjMTWM2OD13LkK0JJBO NUP5XGhoW0GQR1XS
SF539 Mnj6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PLSGlEPTB;MUGuOkBxVQ>? MYLTRW5ITVJ?
ES4 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HLS2lEPTB;MkGuOUBxVQ>? MmfzV2FPT0WU
RL95-2 NVv1S|dKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTlOJhDUUN3ME2xNFcheE1? MVvTRW5ITVJ?
LC-2-ad NITpWIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTR{MzDwUS=> Mn3OV2FPT0WU
Daudi MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTR|NDDwUS=> Ml3iV2FPT0WU
NTERA-S-cl-D1 M{DPSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vMUmlEPTB;NESzJJBO MYPTRW5ITVJ?
OS-RC-2 NFz3SlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHldo9KSzVyPU[1NkBxVQ>? NH;4b3FUSU6JRWK=
VA-ES-BJ NFTaZWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvnW2VKSzVyPUeyN{BxVQ>? NVr1UmNjW0GQR1XS
GR-ST MlnDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nCU2lEPTB;OES2JJBO MnnQV2FPT0WU
SW872 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXXR45KSzVyPUi0OkBxVQ>? NIX5WWFUSU6JRWK=
NOS-1 NGq4Z21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjVcIVIUUN3ME24O|EheE1? NEfqe4NUSU6JRWK=
MC116 NWrEVIhQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HLRmlEPTB;OUi1JJBO MVLTRW5ITVJ?
NCI-H1355 MmrkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPQfnRKSzVyPUGuNFEhdk1? NIHlS2RUSU6JRWK=
RPMI-8226 M1ntbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmL3TWM2OD1zLkG5JI5O M3;BNHNCVkeHUh?=
TE-15 NXvUfFhmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTFwM{[gcm0> MX3TRW5ITVJ?
Ramos-2G6-4C10 M4OyVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\NVVBMUUN3ME2xMlQ3KG6P NGjCNG9USU6JRWK=
KU812 NX;CTHByT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTJwMEGgcm0> M3zaWnNCVkeHUh?=
EW-1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDYTWM2OD1{LkG3JI5O NVjTd4VuW0GQR1XS
KS-1 NVX3UYZUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjoTWM2OD1{LkS1JI5O MoPOV2FPT0WU
SK-LMS-1 NULDNlc6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTJwNEmgcm0> NX;kR2pUW0GQR1XS
TGBC1TKB NUDtS|A6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXPZ3NKSzVyPUKuOlkhdk1? MoDlV2FPT0WU
TE-6 NXzrPYc1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTsTWM2OD1{Lke3JI5O NFLYfWFUSU6JRWK=
ETK-1 NYLCTXhXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTJwOEKgcm0> MnXHV2FPT0WU
BE-13 NGDLRllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrvXXBKSzVyPUKuPVkhdk1? NI\MSpBUSU6JRWK=
A3-KAW NXKxXYhxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrCXIRKSzVyPUKuPVkhdk1? MnLnV2FPT0WU
TE-10 NGjEd3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPo[oUyUUN3ME2zMlMhdk1? MWPTRW5ITVJ?
DOHH-2 M2r3bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHYTmFKSzVyPUOuN|Uhdk1? MVPTRW5ITVJ?
ES6 M2rORmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PpNWlEPTB;Mz60N{BvVQ>? Mk\ZV2FPT0WU
OPM-2 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTRwMUWgcm0> NXzmeXBlW0GQR1XS
SH-4 NY\WXHFXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFruXnFKSzVyPUSuN|Qhdk1? NVHXOXg1W0GQR1XS
NB13 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlGwTWM2OD12LkO2JI5O NIrHXnNUSU6JRWK=
HUTU-80 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\XUm5KSzVyPUSuOFIhdk1? MWrTRW5ITVJ?
CCRF-CEM NXizeI5RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTRwOUSgcm0> NY[2UVNSW0GQR1XS
TGBC24TKB NH6wOZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYP3eZBXUUN3ME21MlUyKG6P NHrpPXNUSU6JRWK=
697 NG\lPG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPBTWM2OD14LkK4JI5O M3TzSnNCVkeHUh?=
J-RT3-T3-5 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLWTWM2OD14LkS2JI5O NYTFVpAxW0GQR1XS
KALS-1 NXHQ[HNWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorlTWM2OD14LkW2JI5O NH7RcYJUSU6JRWK=
no-10 M2XhZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3ntUmlEPTB;Nz6yPUBvVQ>? MnO4V2FPT0WU
SK-NEP-1 NWD3dpl6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXxUJZKSzVyPUiuO|khdk1? M1fHSHNCVkeHUh?=
L-540 M{PaUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPlTWM2OD1zMD60NkBvVQ>? MX;TRW5ITVJ?
JiyoyeP-2003 MlzMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTFyLkm0JI5O NYLzT2NHW0GQR1XS
HH NFjYUppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTFzLkO5JI5O NVnvfJZsW0GQR1XS
SR MoP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PDOmlEPTB;MUGuOFUhdk1? M{TVd3NCVkeHUh?=
QIMR-WIL NGTHT2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTFzLki1JI5O MU\TRW5ITVJ?
A4-Fuk MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjtTWM2OD1zMz6xNkBvVQ>? MmmwV2FPT0WU
CESS MkXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrkRZNKSzVyPUGzMlE{KG6P NV:4bXNNW0GQR1XS
KE-37 MmjjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvae3ZKSzVyPUG2MlA4KG6P MnS3V2FPT0WU
SK-UT-1 NGPwZmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrROmFKSzVyPUG2MlgyKG6P NIPrZmtUSU6JRWK=
SIG-M5 NUDSN3BkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nTV2lEPTB;MUeuNlUhdk1? MWPTRW5ITVJ?
HT NIHrUG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTF5Lk[gcm0> M2nTdnNCVkeHUh?=
DEL M2XYNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUW1WWo5UUN3ME2xO{46QSCwTR?= M4PMcXNCVkeHUh?=
SK-PN-DW MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTJyLkKzJI5O M{nwbXNCVkeHUh?=
RPMI-8402 NVzLRWRFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLZTWM2OD1{MT63O{BvVQ>? NF3ZXnZUSU6JRWK=
RPMI-6666 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3W2OmlEPTB;MkSuOFIhdk1? M4\T[XNCVkeHUh?=
NCI-H720 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPDTWM2OD1{NT60NUBvVQ>? MnXPV2FPT0WU
EW-16 NXXWV3llT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLDTWM2OD1{Nj64O{BvVQ>? NUTzbGxqW0GQR1XS
BL-70 M3LnPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTJ6LkO4JI5O NEjTWpdUSU6JRWK=
SF126 NFXBZpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfWU2NIUUN3ME2zNE4{QCCwTR?= MkDmV2FPT0WU
BC-1 MmS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzQTWM2OD1|MT6yOkBvVQ>? M1rrfnNCVkeHUh?=
MHH-PREB-1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvzTYJKSzVyPUOyMlQ1KG6P MnHrV2FPT0WU
A101D M4fkd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HjUGlEPTB;M{KuOlIhdk1? NHu1[4RUSU6JRWK=
NMC-G1 NXj3RnNvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWi5fW52UUN3ME2zN{43PyCwTR?= NYLZN4hNW0GQR1XS
LB1047-RCC MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLNT2RYUUN3ME2zOE43QSCwTR?= M2TMXXNCVkeHUh?=
EM-2 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\DOnlPUUN3ME2zPE42OyCwTR?= MWHTRW5ITVJ?
COLO-684 MkjHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTN7Lkigcm0> NEKxOFFUSU6JRWK=
Becker M1G3OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTRzLkC1JI5O NUfwNmU5W0GQR1XS
BL-41 MlHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XqTmlEPTB;NEOuOlYhdk1? NGDK[ZhUSU6JRWK=
MDA-MB-134-VI MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFqzO3lKSzVyPUS0MlAzKG6P NETiO5RUSU6JRWK=
L-363 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTR2LkezJI5O MoK1V2FPT0WU
ECC4 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHrWfIpKSzVyPUS0Mlc5KG6P NEXMfHpUSU6JRWK=
A388 M3\kNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjFWIZKSzVyPUS0MlgzKG6P MYTTRW5ITVJ?
HEL MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTtdIdrUUN3ME20PU44QSCwTR?= MlHRV2FPT0WU
RKO M1e5TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEeySI9KSzVyPUWwMlI6KG6P M3nacHNCVkeHUh?=
KINGS-1 NVS4ZXZCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTIXIZZUUN3ME21NU42PSCwTR?= MnXHV2FPT0WU
EB-3 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mkf3TWM2OD13Mj62O{BvVQ>? M4K3W3NCVkeHUh?=
ARH-77 MmPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPGSld6UUN3ME21Nk45KG6P NW\CcYZtW0GQR1XS
GCIY NVnqWINyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTV|LkS2JI5O NILRemtUSU6JRWK=
NCI-H1304 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTV5LkKyJI5O Mk\pV2FPT0WU
KARPAS-299 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHzOWFKSzVyPU[xMlgzKG6P MUDTRW5ITVJ?
IA-LM MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XhUGlEPTB;NkiuNVMhdk1? NI\4NHBUSU6JRWK=
GI-1 NEL0NlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7sVm1KSzVyPUewMlM6KG6P MlfSV2FPT0WU
TE-11 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTWTWM2OD15Nz6xO{BvVQ>? MnfoV2FPT0WU
LS-411N MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfBOW9KSzVyPUe3MlU4KG6P M3\pXnNCVkeHUh?=
no-11 MknLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDUUHpVUUN3ME24N{4zPCCwTR?= NIrXWHFUSU6JRWK=
MV-4-11 M{HDPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPYOJM5UUN3ME24N{44OyCwTR?= M1:4T3NCVkeHUh?=
BV-173 NET4Z5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTh|Lkm3JI5O NWfiRpZVW0GQR1XS
CMK NX\GT2NKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPiTZF1UUN3ME24OE4yPiCwTR?= M2nuO3NCVkeHUh?=
LC4-1 NYPYT5l{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYr2VWNGUUN3ME24Ok44OiCwTR?= NGLFTWxUSU6JRWK=
COR-L279 NHW3WZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDrTWM2OD16Nz6yOUBvVQ>? NILmfHJUSU6JRWK=
NCI-H209 NV74b5ViT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDqOXo6UUN3ME24O{41OSCwTR?= M4e5O3NCVkeHUh?=
Raji NXLGWnpGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTqXohRUUN3ME24PU44OiCwTR?= MWnTRW5ITVJ?
LB996-RCC M3TxdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTl|LkSzJI5O NYTFeJZlW0GQR1XS
NCI-H526 MlPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTl|LkW5JI5O MlzMV2FPT0WU
KGN MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlW4TWM2OD17Nj6yPUBvVQ>? M2fsOHNCVkeHUh?=
MOLT-4 MlztS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYK0bFF5UUN3ME25Ok44QSCwTR?= NUnRZYVjW0GQR1XS
PF-382 NWjkT4VmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mle0TWM2OD17Nj63PUBvVQ>? NVnyO5ByW0GQR1XS
BC-3 NX20Wm1ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LnfmlEPTB;OUmuNVghdk1? MVLTRW5ITVJ?
KARPAS-422 NEXZcFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\4flJnUUN3ME2xNFIvODlibl2= Mm\EV2FPT0WU
SBC-1 NFfn[4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;FV|ZKSzVyPUGwO{44PSCwTR?= NXLlWVBQW0GQR1XS
LC-1F MnjGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;yTGlEPTB;MUC4MlA2KG6P NEfBSoZUSU6JRWK=
GB-1 NGPTe|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;p[mlKSzVyPUGwPU4xOiCwTR?= NVLJcHpWW0GQR1XS
SNB75 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;sRWlEPTB;MUG5MlY6KG6P MXLTRW5ITVJ?
BB65-RCC MoCzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTFzOT65N{BvVQ>? Ml7PV2FPT0WU
NCI-N87 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTF{MT65PEBvVQ>? NEPmZY1USU6JRWK=
IST-MEL1 NEK4WlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTF{Mj6zPEBvVQ>? NHHrfppUSU6JRWK=
HOP-62 MnW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1HrZ2lEPTB;MUK2Mlg6KG6P NXizSZJXW0GQR1XS
ACN M3\TOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\BUZdbUUN3ME2xOFYvPzVibl2= MnnGV2FPT0WU
DMS-114 M2\rcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFi2clBKSzVyPUG1NE43PyCwTR?= MXzTRW5ITVJ?
MLMA MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\EXXR5UUN3ME2xOVkvQDhibl2= MXXTRW5ITVJ?
HT-144 NFTwNlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPmfHM4UUN3ME2xOlUvPDNibl2= Mo[0V2FPT0WU
C2BBe1 NWH0RXRHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13OSWlEPTB;MU[3Mlc3KG6P MnHkV2FPT0WU
L-428 M2Dsfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LO[GlEPTB;MUe3Mlchdk1? NXrVUIc4W0GQR1XS
DU-4475 NIHLbHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTF6Nz62PEBvVQ>? NY\IPWRbW0GQR1XS
CP67-MEL NUG2Wnd7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfnSVdUUUN3ME2xPVkvOzhibl2= MofaV2FPT0WU
MEG-01 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1[y[GlEPTB;MkCxMlk3KG6P Ml\VV2FPT0WU
IST-SL2 M1SzNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmWxTWM2OD1{MEiuOlMhdk1? NXz2VnF4W0GQR1XS
ES8 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PPNWlEPTB;MkK1Mlk1KG6P NXrt[ZhnW0GQR1XS
COLO-800 MkC0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTJ|NT6yPEBvVQ>? NHuzdodUSU6JRWK=
MFH-ino NHX3SotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nGfmlEPTB;MkO1Mlg1KG6P MVPTRW5ITVJ?
OVCAR-4 MmflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTJ|Nz6yOEBvVQ>? MkXOV2FPT0WU
PSN1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo[2TWM2OD1{NEKuO|Ehdk1? NUT4[W9XW0GQR1XS
EW-12 NVnUfYxIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TPeGlEPTB;MkSzMlEhdk1? NEjNZ5dUSU6JRWK=
HCC1599 NIj1TXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfTTWM2OD1{NkGuOFchdk1? NF7jfINUSU6JRWK=
SJSA-1 M1LQeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHNTWM2OD1{N{GuOFYhdk1? NVTWXoJSW0GQR1XS
ST486 M4W2eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPOeW5KSzVyPUK5Ok4yPCCwTR?= NGX5cnVUSU6JRWK=
NOMO-1 M4DGemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDmXW5KSzVyPUOwNE4zOSCwTR?= NV7aUXRbW0GQR1XS
MN-60 M2jpWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljoTWM2OD1|MEWuN|Ihdk1? NIq0RplUSU6JRWK=
HCC1187 MnTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnBVIoyUUN3ME2zNFcvOjVibl2= M{PtNXNCVkeHUh?=
SW982 NVW1WmxiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnO0TWM2OD1|MUSuO|Uhdk1? NWLuR|V7W0GQR1XS
LB647-SCLC MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{Pt[GlEPTB;M{K4MlcyKG6P NFf2NGtUSU6JRWK=
HC-1 MoLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTN|NT61JI5O NVjvdol3W0GQR1XS
EHEB NEPyPFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTocGtKSzVyPUOzO{42OiCwTR?= MoriV2FPT0WU
TUR MmDJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1z0R2lEPTB;M{[zMlk2KG6P NF\pRWZUSU6JRWK=
LU-139 NFTXUlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTN5OD6wNkBvVQ>? MnnYV2FPT0WU
NB1 NXzCV4liT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3f3[GlEPTB;M{i0MlQ2KG6P NGXs[XdUSU6JRWK=
BB30-HNC M1iyS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjmbI5yUUN3ME2zPFgvOzJibl2= MkjIV2FPT0WU
HAL-01 MlvFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHj3W5BKSzVyPUO4PU4zPiCwTR?= Ml3UV2FPT0WU
K5 NV3IRXFtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTBPZptUUN3ME20NVEvOzdibl2= NFjlN|ZUSU6JRWK=
MZ2-MEL NFXKUlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUT4WVNlUUN3ME20NVMvPjRibl2= NWXCc4M1W0GQR1XS
RXF393 M2e1SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{iyNmlEPTB;NEG2MlQ2KG6P NXLm[ZhEW0GQR1XS
NCI-H1648 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUP6U5YzUUN3ME20NVcvPTNibl2= MlS1V2FPT0WU
TE-12 NVnWdJlOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTR|ND6yOkBvVQ>? MnnqV2FPT0WU
EoL-1- NH\kfJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEL2ZndKSzVyPUSzO{46QCCwTR?= NF;KeldUSU6JRWK=
JAR MlP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXCcoU4UUN3ME20N|gvPjJibl2= NETlc|BUSU6JRWK=
DSH1 Mk\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTIdYhKSzVyPUS1PE46OSCwTR?= NGPJZo1USU6JRWK=
NCI-H187 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIi3TG1KSzVyPUS2Nk45OSCwTR?= MVzTRW5ITVJ?
HCE-4 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVf0b3VmUUN3ME20O|cvPjZibl2= M2O0T3NCVkeHUh?=
8-MG-BA Mo\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nacWlEPTB;NUixMlUzKG6P M2HqVHNCVkeHUh?=
KLE MoPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2m3NWlEPTB;NUi1MlIhdk1? M4W5UnNCVkeHUh?=
KNS-42 M3e2Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTV6Nj64NUBvVQ>? NIq1NHVUSU6JRWK=
MSTO-211H NWPRSXgzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\qb2tKSzVyPU[wPU44PCCwTR?= NHO1cIFUSU6JRWK=
GDM-1 NH3IbmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjxcoZKSzVyPU[xOE4xQSCwTR?= MYLTRW5ITVJ?
TE-1 NXTMe4NZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorwTWM2OD14NE[uNVIhdk1? MWTTRW5ITVJ?
BT-474 MnTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTYdWxKSzVyPU[0O{4xPiCwTR?= M4n3WHNCVkeHUh?=
KARPAS-45 M3fWW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYj2fnhvUUN3ME22OFcvPiCwTR?= M1v1[nNCVkeHUh?=
MOLT-16 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTZ2Nz65N{BvVQ>? NVfUOpJ5W0GQR1XS
KURAMOCHI NFWyV4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnKTWM2OD14NUeuOVEhdk1? NH3tRVNUSU6JRWK=
K-562 NWr6d4lJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjqTWM2OD14NkmuOVEhdk1? NELx[HBUSU6JRWK=
EKVX MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPlTWM2OD14N{KuO|Ehdk1? M{XUUnNCVkeHUh?=
GAK Mnv4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTZ5NT6zJI5O MY\TRW5ITVJ?
NCI-SNU-5 Mo\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLRTWM2OD14OUCuNFEhdk1? NHTxOYxUSU6JRWK=
NCI-H2126 M3qycWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLYOJZKSzVyPUeyOk45PyCwTR?= M1XCNHNCVkeHUh?=
CTV-1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTd2ND65JI5O NUG3bW5IW0GQR1XS
SW962 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVqzOoR6UUN3ME23OFgvPDRibl2= MojhV2FPT0WU
MONO-MAC-6 M2PVdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTd3Nj65N{BvVQ>? M3;IVXNCVkeHUh?=
NCI-H748 MkPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTd3OD65PUBvVQ>? NYXzboVmW0GQR1XS
NCI-H524 NEOxfIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjqOGptUUN3ME23PFAvPzNibl2= NXT6bVR4W0GQR1XS
LS-123 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWG1d5JIUUN3ME23PVUvPjlibl2= MofIV2FPT0WU
NB7 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnFUXBKSzVyPUixOE4yPCCwTR?= NFfTOJBUSU6JRWK=
LS-1034 NGDMcYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXm1O5NbUUN3ME24NlgvQThibl2= NV[0Tm1NW0GQR1XS
TE-5 MoH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvzeHllUUN3ME24PFMvPTZibl2= NX7yT4tSW0GQR1XS
A704 MliwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHGXoxKSzVyPUi5PU4yPSCwTR?= NGrDWJhUSU6JRWK=
TK10 NV3jTpRTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PwfGlEPTB;OUG2MlA{KG6P MlPoV2FPT0WU
NCI-H345 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPaXFRHUUN3ME25OFMvOjJibl2= Mo\uV2FPT0WU
CGTH-W-1 NH63OpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;SZWxKSzVyPUm0PE4yOyCwTR?= NG\F[W5USU6JRWK=
NCI-H510A M1HLXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\4XGlEPTB;OUi1MlEzKG6P NUDtUIZ1W0GQR1XS
NCI-H1963 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTFwMEOyPVIh|ryP MnG2V2FPT0WU
SCC-3 NH3zRlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnaVHZKSzVyPUGuNFM1OTRizszN Mn3NV2FPT0WU
EW-11 NGHHbZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTFwMEi3OFMh|ryP NXTQVWdVW0GQR1XS
CPC-N NVj6fFhCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrzTWM2OD1zLkC4PEDPxE1? NHiwOmRUSU6JRWK=
NCI-H1417 MkHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfRWmFNUUN3ME2xMlEzOjZizszN NW\GfHZ6W0GQR1XS
DG-75 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfn[YNoUUN3ME2xMlE3Ojh3IN88US=> NXLhZZRqW0GQR1XS
HD-MY-Z MlHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\mOo92UUN3ME2xMlE3PDF4IN88US=> M1zIOnNCVkeHUh?=
ATN-1 NEHY[YhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PDcGlEPTB;MT6yOlIxQSEQvF2= M2HjNXNCVkeHUh?=
KM-H2 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TsTWlEPTB;MT6yOlQxQCEQvF2= NE\2dGhUSU6JRWK=
NCI-H2081 Mo\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrpTWM2OD1zLkK2OlM4KM7:TR?= NVLjRXhXW0GQR1XS
HL-60 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEizTHdKSzVyPUGuNlY6PTlizszN M3PZenNCVkeHUh?=
DB NF7BNm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jSZ2lEPTB;MT6yO|I1OiEQvF2= NGi3XWdUSU6JRWK=
NCI-H1522 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\0TWM2OD1zLkK4PFg4KM7:TR?= NWDXSHRXW0GQR1XS
AM-38 M4LQVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrZdJpoUUN3ME2xMlMxPzJizszN M17uSnNCVkeHUh?=
NCI-H446 Mn\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPwUIV6UUN3ME2xMlMzOTJzIN88US=> NFzCVGRUSU6JRWK=
SU-DHL-1 M4Tib2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVT2PItwUUN3ME2xMlMzQDBzIN88US=> MXvTRW5ITVJ?
NH-12 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY[4cm84UUN3ME2xMlM3Ozd2IN88US=> NV2xOHpnW0GQR1XS
DMS-79 M2\WdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorhTWM2OD1zLkO2PFY3KM7:TR?= NVHGOJFUW0GQR1XS
NCI-H716 NHr6TFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTFwM{i5PFYh|ryP NHnqXI1USU6JRWK=
ML-2 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vFZWlEPTB;MT60NVUzQSEQvF2= M1vBUHNCVkeHUh?=
NB10 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnu5TWM2OD1zLkS2OlMzKM7:TR?= MYjTRW5ITVJ?
ONS-76 NEDGSlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jxW2lEPTB;MT61N|U3QSEQvF2= NWntPJBXW0GQR1XS
LOUCY NX3zdmpFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfVUFAyUUN3ME2xMlU1PjV5IN88US=> MWPTRW5ITVJ?
SCLC-21H NID3Z41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3qb4tKSzVyPUGuOVg2QDJizszN M{TUUnNCVkeHUh?=
TGW NYLzU|FxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TjcGlEPTB;MT62N|k4PSEQvF2= M3LCc3NCVkeHUh?=
LXF-289 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3joeWlEPTB;MT63N|I3QCEQvF2= Ml3UV2FPT0WU
BB49-HNC M1q5Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPRTWM2OD1zLkezOVg3KM7:TR?= M1nMN3NCVkeHUh?=
NCI-H747 MlG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XZW2lEPTB;MT63OVM1PiEQvF2= M4DaRnNCVkeHUh?=
LU-165 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTFwOES5PFYh|ryP NHzofY1USU6JRWK=
OMC-1 NIjpSnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fKUWlEPTB;MT65OVA3PiEQvF2= NWXRVJBkW0GQR1XS
RCC10RGB M3PGcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TobWlEPTB;MT65OVgyPyEQvF2= M3\0eHNCVkeHUh?=
SW684 NFS2TFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIGwXmJKSzVyPUGuPVYxQTlizszN NUfJ[|dZW0GQR1XS
TE-8 NGD5bnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUGyTYo{UUN3ME2yMlA2PTV7IN88US=> NXvJU|U1W0GQR1XS
SK-N-DZ MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3r5XWlEPTB;Mj6xN|I4PCEQvF2= NGDETHBUSU6JRWK=
EVSA-T NXezUGw{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn22TWM2OD1{LkG3N|E2KM7:TR?= M1GzS3NCVkeHUh?=
KASUMI-1 NGO4fGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlG2TWM2OD1{LkG4PFE2KM7:TR?= NXjFTnJRW0GQR1XS
NKM-1 MoXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4K4ZmlEPTB;Mj6yOVQ4OiEQvF2= NX20RmJsW0GQR1XS
CAL-148 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4L0fGlEPTB;Mj6zN|YyPCEQvF2= NHWxVXBUSU6JRWK=
NCI-H64 M2Oxb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LSVmlEPTB;Mj6zOFI{OiEQvF2= NUXVWW5VW0GQR1XS
KNS-81-FD NHjJb5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvWTWM2OD1{LkO2OlIh|ryP NX\nZY1JW0GQR1XS
KM12 NHPPXXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTJwNEC4N|kh|ryP MWTTRW5ITVJ?
SW954 MonxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXKySI9yUUN3ME2yMlQ4Pzd7IN88US=> MlHiV2FPT0WU
NCI-H1395 Mn;GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXlTWM2OD1{LkWyOlQ2KM7:TR?= M4HqbXNCVkeHUh?=
DJM-1 M37ZOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnPTWM2OD1{Lk[wOlMh|ryP NYTN[WlbW0GQR1XS
COLO-668 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnhS4R1UUN3ME2yMlgzPjl3IN88US=> MmnaV2FPT0WU
NCI-H1436 NE\NO4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1O2[2lEPTB;Mj64OVYyPSEQvF2= MYrTRW5ITVJ?
LB2241-RCC Ml;yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTJwOE[4N|kh|ryP NGnJcmpUSU6JRWK=
GT3TKB NEDnOopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTJwOEmwOVUh|ryP NUG3UWJKW0GQR1XS
COLO-824 M2DiVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjrUHRKSzVyPUKuPFk4PjhizszN M3PqV3NCVkeHUh?=
ES1 NVSzRmpkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fKVWlEPTB;Mj64PVg4QSEQvF2= MnPjV2FPT0WU
LB771-HNC MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfDfFJKSzVyPUKuPVA6PDZizszN NVm3eW86W0GQR1XS
GI-ME-N NHO5[YlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTNwMEC5NFQh|ryP Mn7yV2FPT0WU
NALM-6 NV;LNoFHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\McZJKSzVyPUOuNFA6OzNizszN MWXTRW5ITVJ?
LU-134-A MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\jbWlEPTB;Mz6wOVQzPSEQvF2= MUPTRW5ITVJ?
DMS-153 M4LBUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEW1SGlKSzVyPUOuNFU5OjRizszN Mm\TV2FPT0WU
MZ1-PC NFTtXGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWm4TnpqUUN3ME2zMlA6ODd6IN88US=> M2HuenNCVkeHUh?=
NCI-H1155 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnQWmZ{UUN3ME2zMlEyPjFizszN MVTTRW5ITVJ?
CAS-1 M17aW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTNwMUO3NFch|ryP M4rjbHNCVkeHUh?=
D-502MG MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfuTWM2OD1|LkG0N|kh|ryP NFzyWpRUSU6JRWK=
NCI-H2141 M1vF[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHX4folKSzVyPUOuNVc1PTJizszN NEPIN2VUSU6JRWK=
NB6 Mn33S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M121W2lEPTB;Mz6xPFI2QSEQvF2= NX6ze2VnW0GQR1XS
NCCIT M1z6fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnmbZNKSzVyPUOuNlE5ODlizszN Mn63V2FPT0WU
NB69 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\tc4x[UUN3ME2zMlMyQDlzIN88US=> NHO5VmFUSU6JRWK=
JVM-2 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDlO2tKSzVyPUOuN|Y1OzNizszN MlvnV2FPT0WU
K052 NIDDOI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofyTWM2OD1|LkO3PVY5KM7:TR?= M1PES3NCVkeHUh?=
HCC2157 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTNwNUOyNlgh|ryP M4DLSHNCVkeHUh?=
KMOE-2 M2TtPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHPU21KUUN3ME2zMlU1OjR{IN88US=> Ml\LV2FPT0WU
SF268 NGK2SWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLV[mtKSzVyPUOuO|E2PTRizszN NInWO2NUSU6JRWK=
CHP-126 M1XW[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILqTo9KSzVyPUOuO|Y1PThizszN MXHTRW5ITVJ?
CP66-MEL M{XVcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLZN4JKSzVyPUOuO|kxQTRizszN Mle5V2FPT0WU
NCI-H69 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGraZnFKSzVyPUSuNFE6OzZizszN NHLvUGdUSU6JRWK=
A253 NHvzVnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPocmd7UUN3ME20MlAzOTBzIN88US=> MVrTRW5ITVJ?
NB14 NUDTU2drT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTRwMUC0O|kh|ryP NV[0ZmF3W0GQR1XS
NCI-H1694 NFSwNVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVW0UGdoUUN3ME20MlE{OTF{IN88US=> NXrmVWo4W0GQR1XS
NCI-H2196 NI\sV45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTRwMUexOlkh|ryP MXHTRW5ITVJ?
TE-9 MlnuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jw[2lEPTB;ND6xO|U5OiEQvF2= Ml36V2FPT0WU
D-283MED NVG2N4NZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTRwMUi4OEDPxE1? NX7qeWY4W0GQR1XS
OCI-AML2 M1LT[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLpTWM2OD12LkG5OFg6KM7:TR?= MoLiV2FPT0WU
D-263MG MlrOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTF[HFKSzVyPUSuNlI6PjFizszN MVPTRW5ITVJ?
MPP-89 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{n3VmlEPTB;ND6yO|MxPCEQvF2= Mkn0V2FPT0WU
LAMA-84 Mne2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTRwM{C0NlEh|ryP NIfCN2RUSU6JRWK=
LB373-MEL-D NH;nUnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\Ve2hKSzVyPUSuN|Y4QDlizszN MmTGV2FPT0WU
UACC-257 M3;uUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XCZmlEPTB;ND6zPVU{PCEQvF2= M1i5R3NCVkeHUh?=
MC-CAR M4nQRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7qdXJlUUN3ME20MlQ{QTlizszN NH\aXXFUSU6JRWK=
COLO-320-HSR NWGwR|JkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXYN3lKSzVyPUSuOFQ1OjdizszN M1jFfnNCVkeHUh?=
P30-OHK M3[ycWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTRwNk[1PFEh|ryP MVTTRW5ITVJ?
UACC-812 M3rSXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjxclFVUUN3ME20MlY6OTZzIN88US=> NHHrNZlUSU6JRWK=
CTB-1 MlPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoX3TWM2OD12LkexOVU2KM7:TR?= MYXTRW5ITVJ?
ALL-PO MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHGTWVpUUN3ME20Mlg1ODd5IN88US=> NX22UY9OW0GQR1XS
SK-MEL-2 NXjSN2V1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnqyTWM2OD12Lki2PVU2KM7:TR?= MnPaV2FPT0WU
TC-YIK MnG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfnVXdJUUN3ME20Mlk4QTR{IN88US=> MWrTRW5ITVJ?
NCI-H1882 NEPGXJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfvTWM2OD13LkCyNFAyKM7:TR?= NU\HZoQxW0GQR1XS
MHH-CALL-2 NWjMdI5jT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\sTmlEPTB;NT6wOVA1OiEQvF2= NVrCT|lHW0GQR1XS
U-87-MG NF7HfndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PPVGlEPTB;NT6wPVQ3PiEQvF2= M3\DSXNCVkeHUh?=
NCI-H1092 NW\OV|MzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTVwMk[1OVUh|ryP MYXTRW5ITVJ?
TE-441-T NHLqN2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTVwMke4NkDPxE1? MkTwV2FPT0WU
SK-MEL-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\hTWM2OD13LkK5NFQ1KM7:TR?= MnniV2FPT0WU
EW-22 NUnvenpQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NID1[HRKSzVyPUWuNlk1PjZizszN MVzTRW5ITVJ?
MZ7-mel NHLqWoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\TTWM2OD13LkSwOlkyKM7:TR?= NYf2[Vh6W0GQR1XS
LP-1 NVzVVpE2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrLSlhKSzVyPUWuOFEzQTFizszN MUDTRW5ITVJ?
NCI-SNU-16 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\D[GlEPTB;NT62OFA4PCEQvF2= NILke4tUSU6JRWK=
LU-65 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1W0b2lEPTB;NT63OlM4OyEQvF2= M2HUWHNCVkeHUh?=
CW-2 MonDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{C0e2lEPTB;NT64OVk2QSEQvF2= M13tOHNCVkeHUh?=
WSU-NHL MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXaOWlRUUN3ME21Mlk2OTd2IN88US=> NUHwXYdrW0GQR1XS
IST-MES1 MofJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2i4TmlEPTB;NT65OVQ1OyEQvF2= NF2xbY1USU6JRWK=
U-266 M2jnc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXUU|NtUUN3ME21Mlk5OjB{IN88US=> MkjxV2FPT0WU
TALL-1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTZwMUS2PFgh|ryP MoSwV2FPT0WU
Calu-6 M1rtNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHz[VlKSzVyPU[uNVU{OTZizszN MUnTRW5ITVJ?
MMAC-SF NVroXnJWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHUT|dXUUN3ME22MlE5PTV4IN88US=> MnPRV2FPT0WU
NCI-H82 NFfMe3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPIcIxMUUN3ME22MlIxPDh7IN88US=> NEjBVHBUSU6JRWK=
RS4-11 NHnEeHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TMcmlEPTB;Nj6yOVg6PyEQvF2= NHnkWJhUSU6JRWK=
SNU-C2B NUjGU3R[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTZwNEC5Olkh|ryP MUfTRW5ITVJ?
BOKU NHjpWGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rLZmlEPTB;Nj60O|U6PyEQvF2= NVPTdmZ[W0GQR1XS
C8166 NXHnSIVyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHwfVZOUUN3ME22MlU2QTF{IN88US=> MWTTRW5ITVJ?
D-247MG M3XoNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF73bJlKSzVyPUeuNFQ{PDdizszN Mon0V2FPT0WU
EW-18 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHIW|VKSzVyPUeuNFczQTJizszN MnHBV2FPT0WU
KG-1 NHXTRWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfRTWM2OD15Lk[yO|M5KM7:TR?= NUP2bmtXW0GQR1XS
REH Ml3yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fpdGlEPTB;Nz62PFExQSEQvF2= NEXiOZFUSU6JRWK=
U-698-M M4fVSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rUNWlEPTB;Nz64OFMyPSEQvF2= NGTsPIRUSU6JRWK=
KP-N-RT-BM-1 NFqz[29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zTc2lEPTB;Nz65N|AzQSEQvF2= NI\Se3RUSU6JRWK=
MS-1 NXjVUXVtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2W4VmlEPTB;Nz65OlA1OSEQvF2= NEDwXXhUSU6JRWK=
SNU-C1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nnVGlEPTB;Nz65PFE6OiEQvF2= NH\uSnFUSU6JRWK=
SK-MM-2 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;hTWM2OD16LkK2NFY2KM7:TR?= NETMbG9USU6JRWK=
LAN-6 M4DDZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrzWWxKSzVyPUiuN|AxODFizszN MUnTRW5ITVJ?
NEC8 M{fwUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;DVItPUUN3ME24MlMxPjlzIN88US=> MX\TRW5ITVJ?
NCI-H1770 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIn1V4RKSzVyPUiuN|gxODJizszN NWfyXWxVW0GQR1XS
D-336MG Mn7rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRThwNECxNVYh|ryP MlXIV2FPT0WU
COLO-829 Mne5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjVRm5KSzVyPUiuOFg5PzlizszN NGXkOGxUSU6JRWK=
LS-513 MkH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELCc2tKSzVyPUiuOVk2QTlizszN NFLJcXlUSU6JRWK=
YT MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;1TWM2OD16Lk[yOFI4KM7:TR?= M2raS3NCVkeHUh?=
EW-24 M33kTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnIN2xVUUN3ME24Mlc3PTRizszN MmjvV2FPT0WU
IST-SL1 NV3sNGo6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\sTWM2OD16Lki2OVQ{KM7:TR?= NVTs[HlqW0GQR1XS
CA46 M4TiOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHIVItCUUN3ME24Mlk2ODl6IN88US=> MY\TRW5ITVJ?
NCI-H1838 NELHfpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRThwOUi2NFIh|ryP Mn\yV2FPT0WU
NCI-H719 NE[1ZlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HNcGlEPTB;OT6yOVI4QSEQvF2= NF3KWYNUSU6JRWK=
HCE-T NH\zNYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHiTWM2OD17LkOwPFUyKM7:TR?= MUTTRW5ITVJ?
A498 NEDvVWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUK4Unh3UUN3ME25MlM3OTJ2IN88US=> NGTVVpZUSU6JRWK=
LB831-BLC M33XPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\QbYZKSzVyPUmuO|Y2OjFizszN NXi5fWY4W0GQR1XS
SKM-1 M3jZN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3LW|FSUUN3ME25Mlg2QTZ|IN88US=> NFnrOopUSU6JRWK=
THP-1 M3S3Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;HUnpFUUN3ME25Mlk3QTF6IN88US=> NH;4VXFUSU6JRWK=
SHP-77 MlPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV:wb49LUUN3ME2xNE41ODdizszN NVPQXZVZW0GQR1XS
EW-3 NHnYcYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUe0b5VUUUN3ME2xNE43Ojh7IN88US=> MYXTRW5ITVJ?
KY821 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTFyLke2N{DPxE1? M3PSOnNCVkeHUh?=
NCI-SNU-1 NYr6ZZI2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILrZWRKSzVyPUGxMlAzOTdizszN NV\lTok1W0GQR1XS
HCC2218 NYnWS5l6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF33WmRKSzVyPUGxMlM6QDZizszN MnzWV2FPT0WU
IM-9 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Moi4TWM2OD1zMT61NVA3KM7:TR?= NIW0UIZUSU6JRWK=
NCI-H889 M1fDeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknHTWM2OD1zMT61N|E{KM7:TR?= MU\TRW5ITVJ?
HDLM-2 NFLmOI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3yyTmlEPTB;MUKuOFE2QSEQvF2= MWnTRW5ITVJ?
LB2518-MEL NHrDN|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDLSXpKSzVyPUGyMlY5OTVizszN Mkj4V2FPT0WU
NCI-H23 NVPmT4FtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTF|LkK0NlUh|ryP MX7TRW5ITVJ?
NB17 NFq0cWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTF|LkS1O|kh|ryP MmDRV2FPT0WU
NCI-H322M M1uyW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHQTpJuUUN3ME2xOE41ODZ6IN88US=> M2\UW3NCVkeHUh?=
SUP-T1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTF2LkSxN{DPxE1? MojsV2FPT0WU
ES3 M{XPNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVq3PXJxUUN3ME2xOU4xPzB|IN88US=> NWTsV5JzW0GQR1XS
ES5 NH3YRpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXPTWM2OD1zNT6wO|g4KM7:TR?= NXjxZXBYW0GQR1XS
NCI-H1650 NH:5WXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{H5cmlEPTB;MUWuOFk4QSEQvF2= M{L4eHNCVkeHUh?=
NCI-H226 MmT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mkm0TWM2OD1zNT64O|Y5KM7:TR?= NV7WUnZNW0GQR1XS
COR-L88 NIjnZYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfBTWM2OD1zNj6zNVQh|ryP MWLTRW5ITVJ?
SCC-15 M4jwT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7iS492UUN3ME2xOk4{QDZ7IN88US=> NY\nVHp{W0GQR1XS
GOTO Ml\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGmyRY1KSzVyPUG2MlQ4QTNizszN Ml7uV2FPT0WU
SIMA NWjDZoFkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXBTWM2OD1zNj60PFAzKM7:TR?= NFT6ZWJUSU6JRWK=
NCI-H1299 NX76V3d4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3:1e2lEPTB;MUeuNVU6OSEQvF2= NIDxNHJUSU6JRWK=
NCI-H1581 MoK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPmNpZKSzVyPUG3MlQzOTlizszN NXOxbFFRW0GQR1XS
MHH-NB-11 Mnv4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWj2[mtHUUN3ME2xO{46Pjh|IN88US=> NFjHU|VUSU6JRWK=
MFM-223 NHjLXG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3qySGlEPTB;MUiuNFU{QCEQvF2= NI[5cpBUSU6JRWK=
ES7 M2jYR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTyN3NQUUN3ME2xPE42PDNzIN88US=> NI[wTIRUSU6JRWK=
JVM-3 MoX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfDOnBtUUN3ME2xPE44OTdizszN MnXHV2FPT0WU
RL MnfUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LacmlEPTB;MkCuN|g5KM7:TR?= M1HwPXNCVkeHUh?=
EC-GI-10 Mnu4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\BTWM2OD1{MT6yNFQyKM7:TR?= MXLTRW5ITVJ?
LNCaP-Clone-FGC MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTJzLk[3Olgh|ryP NX\K[I4yW0GQR1XS
IMR-5 NXTuZWV[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlS5TWM2OD1{MT64OFk1KM7:TR?= NFvsSHZUSU6JRWK=
KP-N-YS Mlf3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTJzLki3OUDPxE1? NX7HVYw3W0GQR1XS
Mo-T NF\vN2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTJ{LkKxPFUh|ryP M2nNZnNCVkeHUh?=
NCI-H128 NXi3[4doT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTJ|LkW4OVMh|ryP NUXzeVNnW0GQR1XS
RH-1 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;GdIlKSzVyPUKzMlc5PjZizszN NW\mc|FmW0GQR1XS
NCI-H2171 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTJ2LkK0PFUh|ryP NGLpNVlUSU6JRWK=
RPMI-8866 M3S4bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTJ4Lke0NkDPxE1? NEDVRXNUSU6JRWK=
SK-N-FI MlnGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTJ5LkO4NVEh|ryP MnXSV2FPT0WU
LOXIMVI MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlG3TWM2OD1{Nz64NFUyKM7:TR?= MonzV2FPT0WU
P31-FUJ M4XoWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTNzLkWzO|Qh|ryP M4f6SnNCVkeHUh?=
KMS-12-PE NXnzOFhVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\ITWM2OD12OT61N|AzKM7:TR?= NH\rZXZUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo試験 Treatment with Rapamycin in vivo specifically blocks targets known to be downstream of mTOR such as the phosphorylation and activation of p70S6K and the release of inhibition of eIF4E by PHAS-1/4E-BP1, leading to complete blockage of the hypertrophic increases in plantaris muscle weight and fibre size. [4] Short-term Rapamycin treatment, even at the lowest dose of 0.16 mg/kg, produces profound inhibition of p70S6K activity, which correlates with increased tumor cell death and necrosis of the Eker renal tumors. [5] Rapamycin inhibits metastatic tumor growth and angiogenesis in CT-26 xenograft models by reducing the production of VEGF and blockage of VEGF-induced endothelial cell signaling. [6] Rapamycin treatment at 4 mg/kg/day significantly reduces tumor growth of C6 xenografts, and tumor vascular permeability. [7]
臨床試験 A Phase II study of Rapamycin to erase angiofibromas in patients with Tuberous Sclerosis Complex (TSC) is currently ongoing.
特集

プロトコル (参考用のみ)

キナーゼアッセイ:

[1]

Immunoblotting for the mTOR kinase assay HEK293 cells are plated at 2-2.5×105 cells/well of a 12-well plate and serum-starved for 24 hours in DMEM. Cells are treated with increasing concentrations of Rapamycin (0.05-50 nM) for 15 minutes at 37 °C. Serum is added to a final concentration of 20% for 30 minutes at 37 °C. Cells are lysed, and cell lysates are separated by SDS-PAGE. Resolved proteins are transferred to a polyvinylidene difluoride membrane and immunoblotted with a phosphospecific primary antibody against Thr-389 of p70 S6 kinase. Data are analyzed using ImageQuant and KaleidaGr

細胞アッセイ:

[3]

細胞株 U87-MG, T98G, and U373-MG
濃度 Dissolved in DMSO, final concentrations ~25 μM
反応時間 72 hours
実験の流れ

Cells are exposed to various concentrations of Rapamycin for 72 hours. For the assessment of cell viability, cells are collected by trypsinization, stained with trypan blue, and the viable cells in each well are counted. For the determination of cell cycle, cells are trypsinized, fixed with 70% ethanol, and stained with propidium iodide using a flow cytometry reagent set. Samples are analyzed for DNA content using a FACScan flow cytometer and CellQuest software. For apoptosis detection, cells are stained with the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) technique using an ApopTag apoptosis detection kit. To detect the development of acidic vesicular organelles (AVO), cells are stained with acridine orange (1 μg/mL) for 15 minutes, and examined under a fluorescence microscope. To quantify the development of AVOs, cells are stained with acridine orange (1 μg/mL) for 15 minutes, removed from the plate with trypsin-EDTA, and analyzed using the FACScan flow cytometer and CellQuest software. To analyze the autophagic process, cells are incubated for 10 minutes with 0.05 mM monodansylcadaverine at 37 °C and are then observed under a fluorescence microscope.

動物実験:

[7]

動物モデル Athymic Nu/Nu mice inoculated subcutaneously with VEGF-A-expressing C6 rat glioma cells
製剤 Dissolved in solvent solution (0.2% carboxymethylcellulose and 0.25% Tween-80 in sterile H2O)
投薬量 ~4 mg/kg/day
投与方法 Injection i.p.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)0.020.151.80.40.0810312
Body Surface Area (m2)0.0070.0250.150.050.020.50.240.6
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

参考

化学情報

Download Rapamycin (Sirolimus) SDF
分子量 914.18
化学式

C51H79NO13

CAS No. 53123-88-9
保管 2年-20℃
6月-80℃in solvent
別名 AY 22989,NSC-2260804
溶解度 (25°C) * In vitro DMSO 20 mg/mL (21.87 mM)
<1 mg/mL (<1 mM)
エタノール <1 mg/mL (<1 mM)
In vivo 0.5% CMC+0.25% Tween 80 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethyl]-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone

文献中の引用 (62)

技術サポート&よくある質問(FAQ)

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の質問がある場合は、お気軽くお問合せください。

* 必須

Related mTOR 阻害剤

  • MHY1485

    MHY1485 is a potent, and cell-permeable mTOR activator, and also potently inhibits autophagy.

  • CHIR-99021 (CT99021)

    CHIR-99021(CT99021)は、GSK-3αとGSK-3β阻害剤で、IC50 がそれぞれ 10 nM と 6.7 nMである。

  • Dorsomorphin

  • Afuresertib (GSK2110183)

    Afuresertib (GSK2110183) is a potent, orally bioavailable Akt inhibitor with Ki of 0.08 nM, 2 nM, and 2.6 nM for Akt1, Akt2, and Akt3, respectively. Phase 2.

  • Everolimus (RAD001)

    Everolimus (RAD001) は、1.6-2.4nMのIC50によるFKBP12のmTOR阻害剤です。

  • AZD8055

    AZD8055は、0.8nMのIC50によるmTORの新しいATP競争的阻害剤です。

    Features:First drug to inhibit both types of mTOR protein.

  • Torin 1

    Torin1は、mTORの強力な阻害剤で、IC50 が 2-10 nMです。

  • Temsirolimus (CCI-779, NSC 683864)

    Temsirolimus (CCI-779, NSC 683864)は、特定のmTOR阻害剤で、IC50 が 1.76 μM。

  • INK 128 (MLN0128)

    INK 128 (MLN0128)は、有力で選択的なmTOR 阻害剤で、 IC50 が 1 nMです。

最近チェックしたアイテム

Tags: Rapamycin (Sirolimus)を買う | Rapamycin (Sirolimus)供給者 | Rapamycin (Sirolimus)を購入する | Rapamycin (Sirolimus)費用 | Rapamycin (Sirolimus)生産者 | オーダーRapamycin (Sirolimus) | Rapamycin (Sirolimus)代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
お問い合わせ